MilesR., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients.Kidney Int2009; 76(6): 622–8.
3.
FlynnJ.T., MeislichD., KaiserB.A., PolinskyM.S., BaluarteH.J.Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature.Perit Dial Int1995; 16: 52–7.
4.
HospenthalD.R.Uncommon fungi and prototheca. In: MandellG.L., BennettJ.E., DolinR.Principles and practice of infectious diseases.7th ed.Philadelphia: Churchill Livingstone; 2010: 3365–76.
5.
GaurS., RajgopalA., AshbeeR.A successfully treated case of peritonitis due to Fusarium dimerum.J Infect2010; 61: 86–8.
6.
MuhammedM., ColemanJ., CarneiroH.A., MylonakisE.The challenge of managing fusariosis.Virulence2011; 2(2): 91–6.
7.
GarbinoJ., UckayI., RohnerP., LewD., Van DeldenC.Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature.Transpl Int2005; 18(5): 613–8.
8.
LewisR.E.Antifungal therapeutic drug monitoring.Curr Fungal Infect Rep2010; 4: 158–67.
9.
MorrisM.I.Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.Am J Health-Syst Pharm2009; 66: 225–36.
10.
FreifeldA., ProiaL., AndesD., BaddourL.M., BlairJ., SpellbergB.Voriconazole use for endemic fungal infections.Antimicrob Agents Chemother2009; 53(4): 1648–51.
11.
LiR., CiblakM.A., NordoffN., PasarellL., WarnockD.W., McGinnisM.R.In vitro activities of voriconazole, itraconazole and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.Antimicrob Agents Chemother2000; 44(6): 1734–6.
12.
WheatL.J., ConnollyP., SmedemaM., DurkinM., BrizendineE., MannP.Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.J Antimicrob Chemother2006; 57(6): 1235–9.
13.
RestrepoA., TobonA., ClarkB., GrahamD.R., BradsherR.W., GoldmanM.Salvage treatment of histoplasmosis with posaconazole.J Infect2007; 54(4): 319–27.
